LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.49 2.76

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.49

Max

1.52

Belangrijke statistieken
By Trading Economics
Werknemers	37

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+163.16% upside

Dividenden
By Dow Jones
Volgende Winsten	12 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	30M 94M
Vorige openingsprijs	-1.27
Vorige sluitingsprijs	1.49

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 nov 2025, 21:06 UTC

Belangrijke Marktbewegers

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 nov 2025, 13:10 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 03:50 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Winsten

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Winsten

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Winsten

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Marktinformatie

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Winsten

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Marktinformatie

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Marktinformatie

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Winsten

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Winsten

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Marktinformatie

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Marktinformatie

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

7 nov 2025, 17:17 UTC

Acquisities, Fusies, Overnames

Satair Expects to Complete Purchase in Early 2026

7 nov 2025, 17:17 UTC

Acquisities, Fusies, Overnames

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 nov 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

163.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD 163.16%

Hoogste 4 USD

Laagste 4 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.